Microgen Scientific and Production Association (an affiliate of the Rostec's Nacimbio holding company) has developed the first Russian live anti-flu vaccine in liquid form that does not require intramuscular injection. The drug has successfully passed through Phase I clinical trial confirming its safety.
As was noted by Kirill Gaidash, CEO of Microgen, development of new product forms that would decrease the injury rate during therapies is a key task of the global pharmaceutical community. "Our new anti-flu vaccine in the form of nasal spray will allow to significantly simplify the vaccination process by making it quicker, safer and more comfortable," added he.
According to the holding company, development of the new vaccine is based on Ultravac – a proven live anti-flu vaccine produced by Microgen in dry form for solution preparation. The drug has been widely used in clinical practice with more than 100 million people vaccinated in Russia. Unlike Ultravac, the brand new product does not require the active ingredient to be mixed with a solvent. It will be produced in a ready-to-use form as a liquid drug.
Following all clinical trials the drug will be used for preventing influenza in children aged 3 and above, and adults.
Microgen ensures the supply of about 70% of the total volume of vaccines under the National Preventive Vaccine Calendar (NPVC). The company is the only Russian producer of the live anti-flu vaccine. The company's product portfolio includes more than 250 drugs.
